Adar1 Capital Management, Llc Buys 6,009 Shares of Rallybio (NASDAQ:RLYB) Stock

Rallybio Corporation (NASDAQ:RLYB) major shareholder Adar1 Capital Management, Llc purchased 6,009 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was purchased at an average price of $13.98 per share, for a total transaction of $84,005.82. Following the completion of the transaction, the insider directly owned 916,152 shares in the company, valued at $12,807,804.96. This trade represents a 0.66% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Tuesday, May 19th, Adar1 Capital Management, Llc purchased 10,200 shares of Rallybio stock. The stock was purchased at an average price of $13.98 per share, for a total transaction of $142,596.00.
• On Friday, May 15th, Adar1 Capital Management, Llc purchased 300 shares of Rallybio stock. The stock was purchased at an average price of $13.90 per share, for a total transaction of $4,170.00.
• On Wednesday, May 13th, Adar1 Capital Management, Llc purchased 79,259 shares of Rallybio stock. The stock was purchased at an average price of $13.99 per share, for a total transaction of $1,108,833.41.
• On Tuesday, May 12th, Adar1 Capital Management, Llc purchased 800 shares of Rallybio stock. The stock was purchased at an average price of $13.83 per share, for a total transaction of $11,064.00.
• On Monday, May 11th, Adar1 Capital Management, Llc purchased 50,000 shares of Rallybio stock. The stock was purchased at an average price of $14.00 per share, for a total transaction of $700,000.00.
• On Tuesday, May 5th, Adar1 Capital Management, Llc purchased 35,101 shares of Rallybio stock. The stock was purchased at an average price of $14.00 per share, for a total transaction of $491,414.00.
• On Monday, May 4th, Adar1 Capital Management, Llc purchased 120,804 shares of Rallybio stock. The stock was purchased at an average price of $13.97 per share, for a total transaction of $1,687,631.88.

Rallybio Price Performance

Shares of NASDAQ:RLYB opened at $15.38 on Friday. The company has a market capitalization of $81.48 million, a price-to-earnings ratio of -3.54 and a beta of -1.10. The firm’s 50 day simple moving average is $10.16 and its 200 day simple moving average is $7.32. Rallybio Corporation has a fifty-two week low of $2.16 and a fifty-two week high of $15.75.

Rallybio (NASDAQ:RLYB) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.26). The firm had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.21 million. Rallybio had a negative net margin of 911.07% and a negative return on equity of 55.79%.

Institutional Trading of Rallybio

Hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC raised its holdings in shares of Rallybio by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after purchasing an additional 2,996 shares during the last quarter. XTX Topco Ltd raised its holdings in shares of Rallybio by 64.6% in the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after purchasing an additional 38,205 shares during the last quarter. Susquehanna International Group LLP raised its holdings in shares of Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after purchasing an additional 113,031 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Rallybio by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after purchasing an additional 120,892 shares during the last quarter. Finally, Citadel Advisors LLC raised its holdings in shares of Rallybio by 576.1% in the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after purchasing an additional 373,821 shares during the last quarter. 90.34% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Rallybio in a report on Friday, May 8th. Wall Street Zen upgraded shares of Rallybio to a “hold” rating in a report on Saturday, March 28th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.